abstract |
New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects, of the structural formula <IMAGE> I and therapeutically acceptable salts thereof, in which formula R, R1 and R2 are as follows: R is selected from the group consisting of -C(CH3)3, <IMAGE> R1 is selected from the group consisting of H and R2; R2 is selected from the group consisting of <IMAGE> <IMAGE> and <IMAGE> in which formulas R3 is selected from the group consisting of (a) H; <IMAGE> wherein R5 is a straight or branched alkyl group containing 1-4 carbon atoms; and <IMAGE> and wherein R4 is selected from the group consisting of (a) H (b) an alkyl group containing 1-3 carbon atoms, process for the preparation thereof, chemical intermediates at their preparation, pharmaceutical compositions containing them and their medicinal use. |